Labels The Issue For Viatris Again As It Recalls Insulin Glargine Biosimilar
Bernstein: Recall Could ‘Spell Problem’ For Biocon-Manufactured Product
A further voluntary recall for Viatris’ insulin glargine biosimilar, this time for one of its recently launched interchangeable products, because of missing labels may draw unwanted interest from the US FDA, a leading analyst has warned.
You may also be interested in...
Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.
Just-in-time education may be preferred, so patients and providers see it as they are making decisions, OTBB Director Sarah Yim says in an interview.
Viatris has recalled a batch of its unbranded insulin glargine injector pens after a manufacturing error meant some pens might be missing labels. It is the third time this year the firm has had to recall an insulin product due to a labelling error.